EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
DrugGA: Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral) Tablet, p.o. (oral)
NCT Number: NCT00206583
The purpose of this study is to determine whether the study drug is safe and effective in the prevention of pregnancies in a large group of volunteers.
Looking for future studies?
Notify Me18 year–35 year
Female
Interventional
Phase 3
Total Concept Health Care Inc., Kitchener, Ontario, Canada
This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals Inc.. Bayer HealthCare Pharmaceuticals Inc. is the sponsor of the trial.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
GA: Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral) Tablet, p.o. (oral)
Time frame: Throughout 1 year of treatment
Time frame: Throughout 1 year of treatment
Bayer
Industry
A Multicenter, Open-label Uncontrolled Study to Investigate the Efficacy and Safety of a 4-phasic Oral Contraceptive SH T0065 in a 28-day Regimen for 13 Cycles in Healthy Female Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06557499
Contraception
Berkeley, California, United States
View Trial DetailsNCT07326007
Contraception
Giza, Egypt
View Trial DetailsNCT05732142
Contraception, Gender Equity
La Jolla, California, United States
View Trial DetailsNCT03127722
Contraception
Chandler, Arizona, United States
View Trial Details